- Home
- ARE vs MRNA Comparison
ARE vs MRNA Comparison
Compare ARE & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARE
- MRNA
- Stock Information
- Founded
- ARE 1994
- MRNA 2010
- Country
- ARE United States
- MRNA United States
- Employees
- ARE N/A
- MRNA N/A
- Industry
- ARE Real Estate Investment Trusts
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARE Real Estate
- MRNA Health Care
- Exchange
- ARE Nasdaq
- MRNA Nasdaq
- Market Cap
- ARE 17.5B
- MRNA 16.0B
- IPO Year
- ARE 1997
- MRNA 2018
- Fundamental
- Price
- ARE $93.17
- MRNA $27.58
- Analyst Decision
- ARE Hold
- MRNA Hold
- Analyst Count
- ARE 9
- MRNA 20
- Target Price
- ARE $120.00
- MRNA $54.82
- AVG Volume (30 Days)
- ARE 1.1M
- MRNA 9.3M
- Earning Date
- ARE 04-28-2025
- MRNA 05-01-2025
- Dividend Yield
- ARE 5.52%
- MRNA N/A
- EPS Growth
- ARE 233.15
- MRNA N/A
- EPS
- ARE 1.80
- MRNA N/A
- Revenue
- ARE $3,123,453,000.00
- MRNA $3,236,000,000.00
- Revenue This Year
- ARE N/A
- MRNA N/A
- Revenue Next Year
- ARE $4.63
- MRNA $23.65
- P/E Ratio
- ARE $53.14
- MRNA N/A
- Revenue Growth
- ARE 8.20
- MRNA N/A
- 52 Week Low
- ARE $93.25
- MRNA $29.25
- 52 Week High
- ARE $130.14
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- ARE 42.03
- MRNA 41.10
- Support Level
- ARE $95.06
- MRNA $31.52
- Resistance Level
- ARE $97.67
- MRNA $34.87
- Average True Range (ATR)
- ARE 2.26
- MRNA 1.83
- MACD
- ARE -0.42
- MRNA -0.17
- Stochastic Oscillator
- ARE 9.17
- MRNA 1.41
About ARE Alexandria Real Estate Equities Inc.
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.